Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for the treatment of rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for the treatment of anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Â- Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Overall MarketRank^™

2.29 out of 5 stars

Medical Sector

16th out of 2,041 stocks

Biological Products, Except Diagnostic Industry

2nd out of 176 stocks

4.3 Analyst's Opinion

Consensus Rating
Neurocrine Biosciences has received a consensus rating of Buy. The company's average rating score is 2.65, and is based on 13 buy ratings, 7 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $127.83, Neurocrine Biosciences has a forecasted upside of 40.1% from its current price of $91.22.
Amount of Analyst Coverage
Neurocrine Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.6 Community Rank

Outperform Votes
Neurocrine Biosciences has received 896 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Neurocrine Biosciences has received 357 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Neurocrine Biosciences has received 71.51% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote “Outperform” if you believe NBIX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Neurocrine Biosciences does not currently pay a dividend.
Dividend Growth
Neurocrine Biosciences does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,041,735.00 in company stock.
Percentage Held by Insiders
Only 4.30% of the stock of Neurocrine Biosciences is held by insiders.
Percentage Held by Institutions
95.25% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Neurocrine Biosciences are expected to grow by 191.94% in the coming year, from $1.24 to $3.62 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Neurocrine Biosciences is 98.09, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.07.
Price to Earnings Ratio vs. Sector
The P/E ratio of Neurocrine Biosciences is 98.09, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 43.71.
Price to Book Value per Share Ratio
Neurocrine Biosciences has a P/B Ratio of 13.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

Is Neurocrine Biosciences a buy right now?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 7 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Neurocrine Biosciences stock.
View analyst ratings for Neurocrine Biosciences or view top-rated stocks.

What stocks does MarketBeat like better than Neurocrine Biosciences?

Wall Street analysts have given Neurocrine Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Neurocrine Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Neurocrine Biosciences?

Neurocrine Biosciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 7,000,000 shares, an increase of 57.3% from the March 15th total of 4,450,000 shares. Based on an average daily volume of 1,260,000 shares, the short-interest ratio is currently 5.6 days.
View Neurocrine Biosciences' Short Interest.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for Neurocrine Biosciences.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings data on Tuesday, May, 4th. The company reported $0.33 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.47 by $0.14. Neurocrine Biosciences had a net margin of 8.96% and a trailing twelve-month return on equity of 18.18%.
View Neurocrine Biosciences' earnings history.

How has Neurocrine Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Neurocrine Biosciences' stock was trading at $85.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NBIX stock has increased by 6.0% and is now trading at $91.03.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for NBIX?

20 equities research analysts have issued twelve-month target prices for Neurocrine Biosciences' shares. Their forecasts range from $90.00 to $163.00. On average, they expect Neurocrine Biosciences' stock price to reach $127.83 in the next twelve months. This suggests a possible upside of 40.4% from the stock's current price.
View analysts' price targets for Neurocrine Biosciences or view top-rated stocks among Wall Street analysts.

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the following people:

Dr. Kevin C. Gorman, CEO & Director (Age 63, Pay $1.45M)
Mr. Matthew C. Abernethy, Chief Financial Officer (Age 41, Pay $822.74k)
Dr. Haig P. Bozigian, Chief Devel. Officer (Age 63, Pay $780.63k)
Mr. Eric S. Benevich, Chief Commercial Officer (Age 56, Pay $793.07k)
Ms. Eiry Wyn Roberts, Chief Medical Officer (Age 57, Pay $899.55k)
Dr. Dimitri E. Grigoriadis, Chief Research Officer (Age 63)
Jane Sorensen, Head of Investor Relations
Mr. Darin M. Lippoldt, Chief Legal Officer & Corp. Sec. (Age 55)
Mr. Kyle W. Gano, Chief Bus. Devel. and Strategy Officer (Age 48)
Ms. Julie Cooke, Chief HR Officer (Age 55)

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences CEO Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among Neurocrine Biosciences' employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Neurocrine Biosciences' key competitors?

Some companies that are related to Neurocrine Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of NBIX's competitors.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), The Walt Disney (DIS), Tesla (TSLA), Square (SQ) and salesforce.com (CRM).

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Congress Asset Management Co. MA (0.95%), Swiss National Bank (0.36%), Sumitomo Mitsui Trust Holdings Inc. (0.32%), Rhumbline Advisers (0.27%), Scout Investments Inc. (0.22%) and Alliancebernstein L.P. (0.17%). Company insiders that own Neurocrine Biosciences stock include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy and Stephen A Sherwin.
View institutional ownership trends for Neurocrine Biosciences.

Which major investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Los Angeles Capital Management LLC, Scout Investments Inc., Strs Ohio, Illinois Municipal Retirement Fund, State of New Jersey Common Pension Fund D, Treasurer of the State of North Carolina, and NN Investment Partners Holdings N.V.. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Malcolm Lloyd-Smith, and Matt Abernethy.
View insider buying and selling activity for Neurocrine Biosciences or view top insider-selling stocks.

Which major investors are buying Neurocrine Biosciences stock?

NBIX stock was acquired by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA, Congress Asset Management Co. MA, Rhumbline Advisers, Retirement Systems of Alabama, The Manufacturers Life Insurance Company , Alliancebernstein L.P., DnB Asset Management AS, and Comerica Bank.
View insider buying and selling activity for Neurocrine Biosciences or or view top insider-buying stocks.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $91.03.

How much money does Neurocrine Biosciences make?

Neurocrine Biosciences has a market capitalization of $8.61 billion and generates $788.10 million in revenue each year. The company earns $37.01 million in net income (profit) each year or $0.39 on an earnings per share basis.

How many employees does Neurocrine Biosciences have?

Neurocrine Biosciences employs 845 workers across the globe.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is www.neurocrine.com.

Where are Neurocrine Biosciences' headquarters?

Neurocrine Biosciences is headquartered at 12780 EL CAMINO REAL, SAN DIEGO CA, 92130.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]

This page was last updated on 5/7/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Neurocrine Biosciences Stock Forecast, Price & News

Adding

Adding

Adding Neurocrine Biosciences, Inc.

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Headlines

About Neurocrine Biosciences

MarketRank™

Overall MarketRank™